Doximity, Inc. $DOCS Shares Purchased by Quantinno Capital Management LP

Quantinno Capital Management LP increased its stake in shares of Doximity, Inc. (NYSE:DOCS) by 420.5% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 140,345 shares of the company’s stock after purchasing an additional 113,380 shares during the period. Quantinno Capital Management LP’s holdings in Doximity were worth $3,270,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in DOCS. Vanguard Group Inc. boosted its position in shares of Doximity by 4.1% during the fourth quarter. Vanguard Group Inc. now owns 13,285,485 shares of the company’s stock worth $588,281,000 after buying an additional 518,916 shares during the period. UBS Group AG lifted its stake in Doximity by 26.5% during the 4th quarter. UBS Group AG now owns 680,260 shares of the company’s stock worth $30,122,000 after acquiring an additional 142,408 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in Doximity by 325,436.6% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,298,891 shares of the company’s stock valued at $57,515,000 after acquiring an additional 1,298,492 shares during the period. Rhenman & Partners Asset Management AB grew its position in Doximity by 174.1% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 372,750 shares of the company’s stock valued at $16,505,000 after acquiring an additional 236,750 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of Doximity by 108.5% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 173,621 shares of the company’s stock valued at $7,688,000 after purchasing an additional 90,341 shares during the period. Institutional investors and hedge funds own 87.19% of the company’s stock.

Doximity Price Performance

NYSE:DOCS opened at $27.35 on Friday. The firm has a market capitalization of $5.00 billion, a PE ratio of 32.18, a price-to-earnings-growth ratio of 9.94 and a beta of 1.29. The business’s fifty day moving average price is $21.28 and its 200 day moving average price is $24.37. Doximity, Inc. has a 12 month low of $17.15 and a 12 month high of $76.51.

Doximity (NYSE:DOCS) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.16 by $0.13. The company had revenue of $156.62 million during the quarter. Doximity had a return on equity of 17.65% and a net margin of 25.48%.The firm’s quarterly revenue was up 7.3% on a year-over-year basis. During the same period last year, the firm earned $0.36 earnings per share. As a group, equities analysts anticipate that Doximity, Inc. will post 0.87 EPS for the current year.

Key Headlines Impacting Doximity

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Doximity reported fiscal Q1 revenue of $156.6 million, up 7.3% year over year, and adjusted earnings of $0.29 per share. Revenue exceeded expectations, while the company’s profitability and 30.4% net margin remained notable. Doximity earnings report
• Positive Sentiment: Management raised fiscal 2027 revenue guidance to $671 million-$681 million, slightly above the analyst consensus of $670.4 million. The outlook reflects anticipated demand from pharmaceutical customers and continued adoption of Doximity’s AI capabilities. Doximity Q1 earnings and guidance
• Positive Sentiment: The CEO said Doximity’s clinical AI search generates roughly 10 times more revenue than it costs to operate, while AI-driven engagement is outperforming expectations. Investors view this as a potential source of future monetization that is not fully reflected in current forecasts. CNBC Doximity AI report
• Positive Sentiment: Analysts raised their targets: Piper Sandler maintained an overweight rating and lifted its target to $47 from $42, while JPMorgan raised its target to $31 from $26 but retained a neutral rating. Analyst target changes
• Neutral Sentiment: Doximity’s addition or reclassification within the Russell 1000 may broaden institutional visibility and affect index-related trading, but it does not directly change the company’s fundamentals. Russell 1000 reclassification
• Negative Sentiment: Adjusted earnings fell from $0.36 per share a year earlier, and some estimates showed a slight earnings miss. Higher AI investment is pressuring margins, while critics argue the rally may have moved ahead of near-term fundamentals and could reverse. Doximity rally analysis

Analyst Upgrades and Downgrades

DOCS has been the topic of several recent research reports. The Goldman Sachs Group cut their target price on shares of Doximity from $28.00 to $24.00 and set a “neutral” rating on the stock in a research note on Thursday, May 14th. Evercore set a $40.00 price target on shares of Doximity in a research report on Friday. Morgan Stanley dropped their price target on shares of Doximity from $49.00 to $35.00 and set an “overweight” rating for the company in a research note on Thursday, May 14th. Bank of America reaffirmed an “underperform” rating and set a $20.00 price objective (down from $38.00) on shares of Doximity in a research report on Monday, June 29th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $41.00 target price on shares of Doximity in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $31.86.

Insiders Place Their Bets

In other Doximity news, insider Siddharth Sitaram sold 2,444 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $20.41, for a total transaction of $49,882.04. Following the sale, the insider owned 90,706 shares of the company’s stock, valued at approximately $1,851,309.46. This trade represents a 2.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 31.80% of the company’s stock.

About Doximity

Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.

The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.